Načítá se...
4CPS-157 Vedolizumab: early experience and medium-term outcomes in inflammatory bowel disease
BACKGROUND: Vedolizumab is a monoclonal antibody approved for the treatment of moderate to severe inflammatory bowel disease (IBD) for those patients who have had inadequate or loss of response or were intolerant to a tumour necrosis factor alpha inhibitor (anti-TNF-alpha). PURPOSE: To assess prescr...
Uloženo v:
| Vydáno v: | Eur J Hosp Pharm |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Group
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535236/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.248 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|